Haemonetics heads into the summer with a split personality: the analyst community is upgrading its view just as short sellers add to their bets — a tension the stock's recent price action has not yet resolved.
The clearest signal this week comes from the Street, where the direction of travel has turned meaningfully more positive after months of target cuts. Mizuho raised its price target to $85 from $70 on June 15, maintaining an Outperform rating — a notable reversal after the same firm had trimmed to $70 in April. Bank of America went further in late May, upgrading HAE to Buy from Neutral and lifting its target to $80. BTIG reiterated Buy at $84 on June 17. The consensus target now rests at $85.20, implying roughly 14% upside from Monday's close of $74.43. Not every firm is leaning in: JPMorgan cut its target to $62 in May and holds a Neutral, and Citigroup — which has trimmed its target repeatedly since February — moved to $70 in late May, still short of where the stock is now trading. The shape of recent analyst activity is one of net upgrades with the more cautious names anchoring below the current price. The forward earnings picture adds texture: the 12-month forward EPS growth estimate ranks in the 78th percentile versus peers, and the analyst recommendation divergence factor scores near the top of the universe at the 94th percentile — meaning HAE's bull-bear gap is unusually wide.
Short interest tells a more complicated story. Bears have been quietly rebuilding. Short interest climbed roughly 45% over the past month to 6.2% of the free float — a meaningful increase from the approximately 4.3% level in mid-May — and rose another 8% on the week to around 2.9 million shares. That is high enough to be worth watching, particularly given that the stock gained 32% in the month of May before giving back 5.4% this week. Yet the lending market offers little comfort to those hoping for a squeeze: availability is extremely loose at 1,750%, meaning shares available to borrow outnumber shares already borrowed by a factor of roughly 17. Cost to borrow is just 0.42%, a 17% drop on the week, and availability has actually widened compared to a week ago. The borrow setup characterises the short build as deliberate and low-friction rather than desperate or crowded — shorts are adding into the rally without facing any real cost penalty.
Options traders nudged more defensive this week without sending a strong alarm. The put/call ratio edged up to 0.26, roughly two standard deviations above its 20-day average of 0.20 — a mild elevated reading, though still well below the 52-week high of 1.46. Given how low the absolute PCR is, the z-score overstates the drama; this looks more like routine hedging against a stock that has moved 32% in a month than outright bearish positioning.
One development worth noting on the institutional side is the cluster of insider selling that preceded the May rally. On May 15, the CEO, CFO, COO, General Counsel, and Chief Commercial Officer all sold shares at around $56.29, collectively reducing holdings by a combined 16,500 shares. The trades carried low significance scores and were likely pre-scheduled, but the irony is stark: insiders sold at prices roughly 30% below where the stock closed this week. The 90-day net insider position is slightly positive in share terms at 18,896 shares, but that reflects small offsetting purchases rather than conviction buying.
The next earnings event is scheduled for August 6. The most recent print in May produced a 4.7% one-day gain and an 8.4% five-day gain — so the market rewarded the last release, which partly explains the rally and the subsequent short rebuild. With the stock now trading above most analyst targets except the most bullish names, and shorts up sharply against a backdrop of frictionless borrowing, the August print becomes the next test of whether the upgraded consensus view holds.
See the live data behind this article on ORTEX.
Open HAE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
